Sydney, Australia 4 July 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Kathleen Miller, a US based experienced business development executive, to Clarity’s team. Dr Miller has over 25 years of experience in the pharmaceutical, medical imaging, and medical device industries,…
Sydney, Australia, 29 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has raised AU$4 million to develop its clinical pipeline using its proprietary theranostic technology and expand its presence in Europe and the US. The investment round includes strong support from current shareholders and a small number of…
Sydney, Australia 9 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the presentation of their poster at the upcoming 2017 Annual Meeting of Society for Nuclear Medicine and Medical Imaging (SNMMI) in Denver. Clarity’s Head of Quality, Dr Colin Biggin (also with RNT consulting),…
Sydney, Australia 19 January 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Colin Biggin as Head of Quality at Clarity. Dr Biggin has over 15 years’ experience in radiochemistry and radiopharmaceutical development. His most recent full-time role was with Algeta…
Sydney, Australia 11 August 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, including cancer and heart disease, has been awarded a Belgium government grant of approximately EUR950,000 under the Wallonia region COOTECH program. The grant is funded by the European Union and the Directorate General for Economy, Employment…
Sydney, Australia 27 June 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious diseases, especially cancer, has been awarded a Cooperative Research Centres Projects (CRC-P) grant. This grant is part of the Australian Government’s Cooperative Research Centres Programme. The grant, valued at $2,513,000, will fund the extension of Clarity’s capabilities of…
Clarity Pharmaceuticals pioneers world first use of copper radioisotopes for diagnosis, dosimetry and treatment of cancer Sydney, Australia, 24 May 2016 – Clarity Pharmaceuticals, an emerging Australian biotech company specialising in the treatment of serious disease, has raised AU$2 million to develop its clinical pipeline using its proprietary drug targeting technology. The investment round includes…
Sydney, Australia 11 April 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the results of its clinical trial data for its lead product SARTATE™ will be presented by its collaborators at the Peter MacCallum Cancer Centre at the 2016 Society of Nuclear Medicine and Molecular…
Sydney, Australia 29 March 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Chris Roberts as an independent Non-Executive Director of the Company. Dr Roberts has over 40 years’ experience in the medical innovation space and has served on the boards…
Sydney, Australia 18 March 2016 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded the maximum amount of Accelerating Commercialisation grant funding. This grant is part of the Australian Government’s Entrepreneurs’ Programme and will be used to commercialise Clarity’s novel radiopharmaceutical for treating cancer, SARTATE™. The grant, valued…